Glutathione S‑transferase ω 1 promotes the proliferation, migration and invasion, and inhibits the apoptosis of non‑small cell lung cancer cells, via the JAK/STAT3 signaling pathway

Wang,Kai; Zhang,Fu-Lian; Jia,Wei

doi:10.3892/mmr.2020.11709

Glutathione S‑transferase ω 1 promotes the proliferation, migration and invasion, and inhibits the apoptosis of non‑small cell lung cancer cells, via the JAK/STAT3 signaling pathway

Authors:
- Kai Wang
- Fu-Lian Zhang
- Wei Jia
View Affiliations

Affiliations: Department of Respiratory and Critical Care Medicine, Tianjin Chest Hospital, Tianjin 300222, P.R. China, Integrated TCM and Western Medicine Department, Tianjin Medical University Chu Hsien‑I Memorial Hospital, Tianjin 300134, P.R. China
Published online on: November 20, 2020 https://doi.org/10.3892/mmr.2020.11709
Article Number: 71
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glutathione S‑transferase ω 1 (GSTO1) expression levels have been discovered to be upregulated in various types of cancer. However, to the best of our knowledge, the role of GSTO1 in non‑small cell lung cancer (NSCLC) has not been investigated. The present study aimed to investigate the role of GSTO1 in NSCLC and to determine the potential molecular mechanism. GSTO1 expression levels in A549 cells were knocked down using short hairpin RNA and GSTO1 overexpression in H2122 cells was achieved using cDNA constructs. Reverse transcription‑quantitative PCR was used to analyze the mRNA expression levels of GSTO1. Cell proliferation was determined using a Cell Counting Kit‑8 assay, whereas cell migration and invasion were analyzed using Transwell assays. Flow cytometric analysis was performed to determine the levels of cell apoptosis. The expression levels of GSTO1, Bax, caspase 3, JAK and STAT3 were analyzed using western blotting. The results revealed that GSTO1 overexpression significantly promoted the proliferation, migration and invasion, and inhibited the apoptosis of H2122 cells, whereas the opposite trend was achieved in A549 cells with GSTO1 knockdown. GSTO1 overexpression also significantly increased the phosphorylation levels of JAK and STAT3, whereas the knockdown of GSTO1 promoted the opposite effects. In conclusion, the findings of the present study indicated that GSTO1 may serve as an oncogene in NSCLC. The results suggested that GSTO1 may have an important role in NSCLC by regulating the JAK/STAT3 signaling pathway. Therefore, inhibiting the expression levels of GSTO1 may represent a potential novel therapeutic strategy for NSCLC.

View Figures

View References

1	Herbst RS, Morgensztern D and Boshoff C: The biology and management of non-small cell lung cancer. Nature. 553:446–454. 2018. View Article : Google Scholar : PubMed/NCBI
2	Torre LA, Siegel RL and Jemal A: Lung cancer statistics. Lung Cancer and Personalized medicine. Ahmad A and Gadgeel S: Springer; Cham: pp. 1–19. 2016, View Article : Google Scholar
3	Yang Z, He J, Gao P, Niu Y, Zhang J, Wang L, Liu M, Wei X, Liu C, Zhang C, et al: miR-769-5p suppressed cell proliferation, migration and invasion by targeting TGFBR1 in non-small cell lung carcinoma. Oncotarget. 8:113558–113570. 2017. View Article : Google Scholar : PubMed/NCBI
4	Xu XL, Gong Y and Zhao DP: Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma. Eur Rev Med Pharmacol Sci. 22:8731–8739. 2018.PubMed/NCBI
5	Laskin JJ and Sandler AB: State of the art in therapy for non-small cell lung cancer. Cancer Invest. 23:427–442. 2005. View Article : Google Scholar : PubMed/NCBI
6	She K, Huang J, Zhou H, Huang T, Chen G and He J: lncRNA-SNHG7 promotes the proliferation, migration and invasion and inhibits apoptosis of lung cancer cells by enhancing the FAIM2 expression. Oncol Rep. 36:2673–2680. 2016. View Article : Google Scholar : PubMed/NCBI
7	Manupati K, Debnath S, Goswami K, Bhoj PS, Chandak HS, Bahekar SP and Das A: Glutathione S-transferase omega 1 inhibition activates JNK-mediated apoptotic response in breast cancer stem cells. FEBS J. 286:2167–2192. 2019. View Article : Google Scholar : PubMed/NCBI
8	Whitbread AK, Masoumi A, Tetlow N, Schmuck E, Coggan M and Board PG: Characterization of the omega class of glutathione transferases. Methods Enzymol. 401:78–99. 2005. View Article : Google Scholar : PubMed/NCBI
9	Chirila DN, Chirila MD, Micu BV, et al: The risk of gastric cancer in patients with glutathione s-transferases (GSTS) gene polymorphisms. Hum Vet Med. 10:104–110. 2018.
10	Ada TG, Ada AO, Kunak SC, Alpar S, Gulhan M and Iscan M: Association between glutathione S-transferase omega 1 A140D polymorphism in the Turkish population and susceptibility to non-small cell lung cancer. Arh Hig Rada Toksikol. 64:61–67. 2013. View Article : Google Scholar : PubMed/NCBI
11	Xu YT, Wang J, Yin R, Qiu MT and Xu L, Wang J and Xu L: Genetic polymorphisms in Glutathione S-transferase Omega (GSTO) and cancer risk: A meta-analysis of 20 studies. Sci Rep. 4:65782014. View Article : Google Scholar : PubMed/NCBI
12	Karacaoğlan V, Ada AO, Bilgen S, Çetinkaya GT, Soydaş E, Kunak CS, Alpar SM, Gülhan M and Işcan M: Xenobiotic/drug metabolizing enzyme and TP53 polymorphisms and clinical outcome in advanced nonsmall cell lung cancer patients. Turk J Med Sci. 47:554–562. 2017. View Article : Google Scholar : PubMed/NCBI
13	Bulus H, Oguztuzun S, Guler Simsek G, Kilic M, Oguz Ada A, Göl S, Kaya Kocdogan A, Kaygın P, Bozer B and Iscan M: Expression of CYP and GST in human normal and colon tumor tissues. Biotech Histochem. 94:1–9. 2019. View Article : Google Scholar : PubMed/NCBI
14	Chuang JJ, Dai YC, Lin YL, Chen YY, Lin WH, Chan HL and Liu YW: Downregulation of glutathione S-transferase M1 protein in N-butyl-N-(4-hydroxybutyl)nitrosamine-induced mouse bladder carcinogenesis. Toxicol Appl Pharmacol. 279:322–330. 2014. View Article : Google Scholar : PubMed/NCBI
15	Wang LK, Yue HL, Peng XJ and Zhang SJ: GSTO1 regards as a meritorious regulator in cutaneous malignant melanoma cells. Mol Cell Probes. 48:1014492019. View Article : Google Scholar : PubMed/NCBI
16	Radic T, Coric V, Bukumiric Z, Pljesa-Ercegovac M, Djukic T, Avramovic N, Matic M, Mihailovic S, Dragicevic D, Dzamic Z, et al: GSTO1*CC Genotype (rs4925) Predicts Shorter Survival in Clear Cell Renal Cell Carcinoma Male Patients. Cancers (Basel). 11:20382019. View Article : Google Scholar
17	Piaggi S, Raggi C, Corti A, Pitzalis E, Mascherpa MC, Saviozzi M, Pompella A and Casini AF: Glutathione transferase omega 1-1 (GSTO1-1) plays an anti-apoptotic role in cell resistance to cisplatin toxicity. Carcinogenesis. 31:804–811. 2010. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Ding Y, Lu Y, Xie X, Sheng B and Wang Z: Silencing TRIM37 inhibits the proliferation and migration of non-small cell lung cancer cells. RSC Advances. 8:36852–36857. 2018. View Article : Google Scholar
20	Besse B, Charrier M, Lapierre V, Dansin E, Lantz O, Planchard D, Le Chevalier T, Livartoski A, Barlesi F, Laplanche A, et al: Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC. OncoImmunology. 5:e10710082015. View Article : Google Scholar : PubMed/NCBI
21	Li L, Zhao Y, Cao R, Li L, Cai G, Li J, Qi X, Chen S and Zhang Z: Activity-based protein profiling reveals GSTO1 as the covalent target of piperlongumine and a promising target for combination therapy for cancer. Chem Commun (Camb). 55:4407–4410. 2019. View Article : Google Scholar : PubMed/NCBI
22	Tang SN, Fu J, Shankar S and Srivastava RK: EGCG enhances the therapeutic potential of gemcitabine and CP690550 by inhibiting STAT3 signaling pathway in human pancreatic cancer. PLoS One. 7:e310672012. View Article : Google Scholar : PubMed/NCBI
23	Zhang T, Ma L, Wu P, Li W, Li T, Gu R, Dan X, Li Z, Fan X and Xiao Z: Gallic acid has anticancer activity and enhances the anticancer effects of cisplatin in non small cell lung cancer A549 cells via the JAK/STAT3 signaling pathway. Oncol Rep. 41:1779–1788. 2019.PubMed/NCBI
24	Wen W, Liang W, Wu J, Kowolik CM, Buettner R, Scuto A, Hsieh MY, Hong H, Brown CE, Forman SJ, et al: Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer. Mol Cancer Ther. 13:3037–3048. 2014. View Article : Google Scholar : PubMed/NCBI
25	Zhou F, Cheng L, Qiu LX, Wang MY, Li J, Sun MH, Yang YJ, Wang JC, Jin L, Wang YN, et al: Associations of potentially functional variants in IL-6, JAKs and STAT3 with gastric cancer risk in an eastern Chinese population. Oncotarget. 7:28112–28123. 2016. View Article : Google Scholar : PubMed/NCBI
26	Yang CL, Liu YY, Ma YG, Xue YX, Liu DG, Ren Y, Liu XB, Li Y and Li Z: Curcumin blocks small cell lung cancer cells migration, invasion, angiogenesis, cell cycle and neoplasia through Janus kinase-STAT3 signalling pathway. PLoS One. 7:e379602012. View Article : Google Scholar : PubMed/NCBI